Experience in the use of a modern chondroprotector in patients with primary and secondary osteoarthritis of various localization in the acute stage

In choosing the therapeutic tactics of osteoarthritis, a personalized approach should be used, depending on the prevalence of the pathological process and the presence of background diseases. According to Russian and foreign recommendations, groups of delayedacting drugs that structurally modify cartilage are used as the basic pharmacotherapy of osteoarthritis from the first stages (symptomatic slow-active drug in osteoarthritis – SYSADOA). The aim of this study was to evaluate the efficacy and safety of therapy with an injectable chondroprotector in patients with primary and secondary osteoarthritis of various localizations after a stationary course of basic therapy for rheumatoid arthritis, ankylosing spondylitis, or exacerbation of primary osteoarthritis. The study included 30 patients with rheumatic diseases diagnosed with primary or secondary osteoarthritis against the background of rheumatoid arthritis and ankylosing spondylitis. After a course of basic therapy in the hospital at the outpatient stage, patients received an injectable chondroprotector 1 ml intramuscularly 1 time per day for 20 days according to the instructions for medical use. A comprehensive examination of patients was carried out at the inpatient stage. The severity of the pain syndrome was assessed using a 100 mm visual analogue scale. The degree of pain control was assessed by patients 30 ± 7 days after the start of treatment. Therapy with an injectable chondroprotector in patients with primary and secondary osteoarthritis of various localization makes it possible to achieve a statistically significant decrease in the severity of pain syndrome and improve the functional state of the joints in most patients. The therapy is characterized by a high safety profile and good tolerability. It allows not only to more effectively relieve pain in patients with primary and secondary osteoarthritis, but also to improve the safety of treatment by reducing the risk of adverse events while taking non-steroidal anti-inflammatory drugs, which is especially important given the comorbid profile of most patients with rheumatic joint diseases.

1. Rheumatology / Pod red. E. Alebadzho, L. Danklti: per. s angl. Pod red. dok. med. nauk, prof. A. M. Lila. M.: Medpress-inform, 2022. 304 s.: il.]

2. Textbook of practical rheumatology. Guide for doctors. Rostov-na-Donu, 2016. P. 376.]

3. Vystavkina Ye. Osseous rheumatology. Symptoms, diagnosis, treatment. M.: Eksmo, 2022. P. 404.]

4. Feklistov A. Yu., Vorob'yeva L. D., Alekseyeva O. G., Sukhinina A. V., Andrianova I. A., Men'shikova I. V., Sorotskaya V. N., Zotkin Ye. G. Results of non-interventional clinical study "hummingbird" to assess the efficacy and safety of the use of the drug ambene bio in patients with primary and secondary osteoarthritis of various localization // RMJ. Meditsinskiye obozreniya. 2022; 4 (6).]

5. Rheumatology secrets, fourth edition. Sterling g. West, md, Jason Kolfenbach, md, Elsevier© 2020, 424.

6. Firestein & Kelley’s textbook of rheumatology – e-book, 11th edition, 2-volume set. By Gary s. Firestein, md, Ralph c. Budd, md, Sherine E. Gabriel, md, msc, Iain B. Mcinnes, phd, frcp, frse and James R. O'dell, md; edited by Gary Koretzky, md, 2400 p.

7. Mazurov V. I., Trofimova A. S., Trofimov Ye. A. Risk factors and some aspects of the pathogenesis of osteoarthritis // Vestnik Severo-Zapadnogo gosudarstvennogo meditsinskogo universiteta im. I. I. Mechnikova. 2016; 2 (8): 116-124.]

8. Starodubtseva I. A., Vasil'yeva L. V. Secondary osteoarthritis in rheumatoid arthritis // Klinitsist. 2015; 1 (9): 24-28.]

9. Belyayeva I. B., Mazurov V. I., Trofimova T. N., Trofimov Ye. A. Early rheumatoid arthritis: current diagnostic and treatment options. SPb: Medforum, 2018. P. 136.]

10. Shmidt Ye. I., Akhmedzhanov F. M., Soldatov D. G., Belozerova I. V. Experience with the use of structum in patients with rheumatoid arthritis // Terapevticheskiy arkhiv. 2004; 11 (76): 93-95.]

11. Instructions for the medical use of the drug Ambene Bio / Denisov L. N., Platova A. I., Menshikova I. V., Lila A. M. Osteoartrit – aspekty farmakoterapii // Sovremennaya revmatologiya. 2018; 12.]

12. Amirdzhanova V. N., Erdes Sh. F. Validation of the Russian version of the Euroqol-5d (eq-5d) general questionnaire // Nauchno-prakticheskaya revmatologiya. 2007; 3: 69-75.]